Kura Oncology Inc. (KURA)
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 16, 4:00 PM ET · Delayed 15 min
KURA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $807.76M
- EPS (TTM)
- -$3.37
- Dividend yield
- None
- 52-week range
- 7.36 – 13.90
- Day range
- 9.05 – 9.68
- Volume / Avg
- 1.78M / 1.82M
- Beta
- —
- Shares outstanding
- 88.96M
- Next earnings
- Nov 3, 2026
52-week range
KURA stock today
On Oct 16, KURA ended the session at $9.08, shedding $0.62 (6.39%), versus the S&P 500's 1.09% decline. Shares are 34.7% below their 52-week high of $13.90, set on Aug 25, 2026 and 23.4% above the 52-week low of $7.36, in the middle of the past year's range. KURA is down 12.6% year to date, underperforming the S&P 500 (+11.9%). Over the past 12 months, the stock has lost 10.4%.
Kura Oncology has posted a net loss over the last twelve months (EPS of -$3.37), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 3; analysts expect EPS of -$0.83.
Summary generated from market data by MetaCap's automated system. Methodology
About Kura Oncology
Company profileKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Troy Edward Wilson J.D., Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 260
- Website
- kuraoncology.com
Financial highlights
Full financialsIn fiscal 2025, Kura Oncology generated $67.5 million in revenue, up 25.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Kura Oncology reported a net loss of $278.7 million, compared with a loss of $174.0 million a year earlier. Operating margin was -449.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $67.48M | $53.88M | $0 | — | — |
| Growth | +25.24% | — | — | — | — |
| Net income | $-278.67M | $-173.98M | $-152.63M | $-135.84M | $-130.47M |
| EPS (diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$31.85+250.77%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.83
- Last reported (Q2 2026)
- Aug 12, 2026
- EPS actual vs est.
- $-0.77 vs —
Kura Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics Class A | 9.55 | -6.92% | $812.77M | vs KURA |
| CRVSCorvus Pharmaceuticals Inc. | 9.52 | -3.35% | $800.83M | vs KURA |
| ARDXArdelyx Inc. | 3.09 | -5.50% | $797.80M | vs KURA |
| AVBPArriVent BioPharma Inc. | 16.66 | -0.77% | $821.47M | vs KURA |
| ALMSAlumis Inc. | 6.12 | -3.01% | $792.14M | vs KURA |
| VSTMVerastem Inc. | 8.65 | -6.28% | $783.37M | vs KURA |
| AKTSAktis Oncology Inc. | 15.06 | -5.93% | $837.63M | vs KURA |
| HELPHelus Pharma Inc. | 10.55 | -4.52% | $770.78M | vs KURA |
Indexes, lists and sector
Kura Oncology stock FAQ
What is Kura Oncology's stock price today?
KURA last traded at $9.08 as of Oct 16, 4:00 PM EDT, down 6.39% on the day. Prices are delayed at least 15 minutes.
When is Kura Oncology's next earnings date?
Kura Oncology is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.83.
Who is Kura Oncology's CEO?
Dr. Troy Edward Wilson J.D., Ph.D. is the chief executive officer of Kura Oncology Inc., which has about 260 employees.
What is the KURA 52-week high?
The 52-week high for KURA is $13.90 and the 52-week low is $7.36. The stock is currently 34.7% below its high.